CASP3 and Huntington disease: In addition, using in silico structure-based design coupled with solid-state synthesis, a group of pentapeptide aldehyde compounds were recently developed, and some showed high affinity (IC50 in nanomolar magnitude) and selectivity (60-fold difference in IC50 between Casp2 and caspase-3) to Casp2 [22], drawing attention to the possibility of targeting Casp2 activity as a therapeutic strategy in HD.